Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.85 |
| ▸ | GAA | P10253 | 1/20 | 0.85 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.73 |
| ▸ | CYP2C8 | P10632 | 4/20 | 0.73 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.73 |
| ▸ | CYP2B6 | P20813 | 4/20 | 0.73 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.73 |
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.73 |
| ▸ | LTA4H | P09960 | 3/20 | 0.73 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.73 |
| ▸ | HTR1A | P08908 | 3/20 | 0.72 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.72 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.72 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.72 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.62 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.62 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hexahydrocurcumin SCHEMBL290121 | 0.95 | POLB (0.88) | POLBGAACYP3A4CYP2C8CYP2C9 | |
| Hexahydrocurcumin SCHEMBL29841863 | 0.95 | POLB (0.88) | POLBGAACYP3A4CYP2C8CYP2C9 | |
| Hexahydrocurcumin SCHEMBL21187516 | 0.95 | POLB (0.88) | POLBGAACYP3A4CYP2C8CYP2C9 | |
| SCHEMBL28766005 | 0.92 | GAA (1.00) | POLBGAACYP3A4CYP2C8CYP2C9 | |
| SCHEMBL29908853 | 0.92 | GAA (1.00) | POLBGAACYP3A4CYP2C8CYP2C9 | |
| SCHEMBL32090 | 0.92 | GAA (1.00) | POLBGAACYP3A4CYP2C8CYP2C9 | |
| SCHEMBL5702560 | 0.88 | LTA4H (0.91) | POLBGAACYP3A4CYP2C8CYP2C9 | |
| SCHEMBL20668437 | 0.88 | LTA4H (0.84) | POLBGAACYP3A4CYP2C8CYP2C9 | |
| SCHEMBL31091264 | 0.88 | LTA4H (0.84) | POLBGAACYP3A4CYP2C8CYP2C9 | |
| SCHEMBL25595300 | 0.88 | LTA4H (0.84) | POLBGAACYP3A4CYP2C8CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11707438-B2 | Curcuminoid composition for therapeutic management of metabolic syndrome | SAMI-SABINSA GROUP LIMITED (IN) | 2023-07-25 | — | — | US | disclosed |
| US-11707438-B2 | Curcuminoid composition for therapeutic management of metabolic syndrome | SAMI-SABINSA GROUP LIMITED (IN) | 2023-07-25 | — | — | US | disclosed |
| US-20210106543-A1 | CURCUMINOID COMPOSITION FOR THERAPEUTIC MANAGEMENT OF METABOLIC SYNDROME | MAJEED MUHAMMED (IN) | 2021-04-15 | — | — | US | disclosed |
| US-20210106544-A1 | CURCUMINOID COMPOSITION AND ITS THERAPEUTIC POTENTIAL IN MANAGING LUNG FIBROSIS | SAMI-SABINSA GROUP LIMITED (IN) | 2021-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11707438-B2 | Curcuminoid composition for therapeutic management of metabolic syndrome | CPT1A, GPR119, LIPC | POLB 4169/4885GAA 4493/4885CYP3A4 1949/4885 |
| US-20210106543-A1 | CURCUMINOID COMPOSITION FOR THERAPEUTIC MANAGEMENT OF METABOLIC SYNDROME | CPT1A, GPR119, LIPC | POLB 4169/4885GAA 4493/4885CYP3A4 1949/4885 |
| US-20210106544-A1 | CURCUMINOID COMPOSITION AND ITS THERAPEUTIC POTENTIAL IN MANAGING LUNG FIBROSIS | SFRP1, DKK1, WNT1 | POLB 3770/4885GAA 4870/4885CYP3A4 2915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.